Amarin (AMRN) to Release Quarterly Earnings on Wednesday

Amarin (NASDAQ:AMRN) is projected to issue its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Amarin to post earnings of $0.31 per share and revenue of $42.0380 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.63. The firm had revenue of $72.74 million during the quarter, compared to the consensus estimate of $45.45 million. Amarin had a negative return on equity of 21.18% and a negative net margin of 47.22%. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Price Performance

Shares of Amarin stock opened at $19.24 on Tuesday. The firm’s 50-day moving average is $16.79 and its 200 day moving average is $14.40. The stock has a market cap of $397.88 million, a price-to-earnings ratio of -5.24 and a beta of 0.62. Amarin has a 1 year low of $7.08 and a 1 year high of $20.90.

Institutional Investors Weigh In On Amarin

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp lifted its position in Amarin by 449,522.1% during the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock valued at $815,000 after purchasing an additional 1,811,574 shares in the last quarter. Jump Financial LLC purchased a new stake in Amarin in the second quarter worth about $623,000. Finally, Headlands Technologies LLC bought a new position in shares of Amarin in the second quarter worth about $44,000. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on AMRN. Zacks Research raised Amarin from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Wall Street Zen upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.00.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.